XAGE2: A Potential Drug Target and Biomarker (G9502)

Target Name: XAGE2

NCBI ID: G9502

XAGE2

XAGE2: A Potential Drug Target and Biomarker

XAGE2, also known as XAGE2 protein, is a gene that encodes a protein involved in the regulation of cellular processes essential for cell survival and growth. The XAGE2 gene has been associated with a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders . Its role in these diseases has led to its potential as a drug target or biomarker. In this article, we will explore the biology and potential applications of XAGE2 as a drug target and biomarker.

The XAGE2 gene encodes a protein that belongs to the superfamily of CAA/DAA-repeat proteins. This family of proteins plays a critical role in the regulation of cellular processes, including DNA replication, gene expression, and cellular signaling. XAGE2 is a 21 -kDa protein that contains 11 transmembrane domains and a unique N-terminus. It is expressed in various tissues and cells, including neurons, astrocytes, endothelial cells, and cancer cells.

XAGE2 has been associated with a variety of diseases due to its involvement in various cellular processes that are crucial for human health. One of the most significant association is with cancer. XAGE2 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers. Its overexpression has been associated with poor prognosis and increased tumor progression. Therefore, targeting XAGE2 has been identified as a potential strategy for cancer treatment.

Another potential application of XAGE2 as a drug target is its role in neurodegenerative diseases. neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells that lead to a range of symptoms. has been shown to be involved in the regulation of neurotransmitter synthesis and release, which is critical for the function of neurons. Therefore, targeting XAGE2 may provide new insights into the treatment of neurodegenerative diseases.

In addition to its potential role in cancer and neurodegenerative diseases, XAGE2 has also been associated with autoimmune disorders. autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis, are characterized by the immune system attacking the body's own tissues. shown to be involved in the regulation of immune cell function, including the production of T cells and the regulation of cytokine signaling. Therefore, targeting XAGE2 may provide new insights into the treatment of autoimmune disorders.

Finally, XAGE2 has also been shown to be involved in the regulation of cellular processes that are essential for cell survival and growth. may provide new insights into the treatment of various diseases that are characterized by the dysfunction of cellular processes.

In conclusion, XAGE2 is a gene that encodes a protein involved in the regulation of cellular processes essential for cell survival and growth. Its association with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders, has led to its potential as a drug target or biomarker. Further research is needed to fully understand the role of XAGE2 in these diseases and to develop effective treatments.

Protein Name: X Antigen Family Member 2

The "XAGE2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about XAGE2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets